COHANCE - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 2.3
Show all parameters (20 more)
🧾 Chart Verdict
Short-term entry zones could be established around 425 ₹ – 435 ₹, targeting resistance levels based on previous highs. A stop-loss order should ideally be placed just below the 400 ₹ level to mitigate risk if the bounce fails to materialize. The market is currently exhibiting a bearish tilt given the negative news and high valuation; thus, a cautious approach with tight risk management is warranted.
✅ Positive
The recent uptick in volume alongside a slight dip in the MACD suggests a potential bounce from the lower levels, particularly as the price is approaching a key resistance level near 933 ₹. Furthermore, the RSI reading of 47 indicates that the stock isn’t overbought and still has room to move higher before encountering significant selling pressure.
⚠️ Limitation
The extremely high P/E ratio (87.5) compared to the industry average (34.8) raises concerns about potential overvaluation. This could be exacerbated by the recent negative news regarding promoter stake sales and the USFDA inspection findings. A pullback towards support levels is likely if these concerns persist.
📉 Company Negative News
The USFDA Form 483 with four observations indicates ongoing quality control issues that could negatively impact future revenue growth and investor confidence. The promoters releasing a large stake also signals potential concerns about management’s commitment or an exit strategy, which could further depress the stock price.
🏭 Industry
The pharmaceutical sector is currently facing regulatory headwinds with increased scrutiny from agencies like the USFDA, impacting companies' growth prospects and valuations. Moreover, the industry generally trades at a premium valuation due to the innovation potential of drug development, but this is being tempered by concerns about generic competition and pricing pressures.